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Effects of fluvastatin on insulin resistance
and cardiac morphology in hypertensive
patients
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Division of Nephrology, Hypertension and Cardiovascular Metabology Center, Kidney and Hypertension
Hospital, Federal University of Sa˜o Paulo, Sa˜o Paulo, Brazil
Among hypertensive patients, cardiovascular disease
morbidity is common, even in those who are adequately
treated. New pharmacological strategies to mitigate the
burden of arterial hypertension are needed. This 12-
month, randomized, double-blind placebo-controlled
study investigated the effect of statin (fluvastatin)
treatment on ambulatory blood pressure (ABP), exercise
blood pressure (EBP), myocardial structure, endothelial
function and insulin resistance in 50 hypertensive
patients. At baseline, the groups were comparable in
terms of demographic characteristics, ABP, EBP, en-
dothelial function and homeostasis model assessment
of insulin resistance (HOMA-IR). At the end of the study,
there was no difference between groups in terms of
resting systolic blood pressure. However, maximum
systolic EBP was lower in the treatment group than in
the placebo group (175±18 vs 192±23mmHg, Po0.05),
as was left ventricular mass index (LVMI; 82±15 vs
100±23, Po0.05), and HOMA-IR index was lower after
fluvastatin treatment (2.77±1.46 vs 3.33±1.73, Po0.05).
Changes in lipid profile were not correlated with blood
pressure, endothelial function, LVMI or HOMA-IR data.
In hypertensive patients, fluvastatin can improve max-
imum systolic EBP, myocardial remodelling and insulin
resistance, independently of lipid profile variations and
endothelial function.
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Introduction
The risk of adverse cardiovascular events increases
dramatically when dyslipidaemia and hypertension
co-exist,1,2 and the simultaneous prescription of
antihypertensive and hypolipidaemic agents is
common. Addition of hypolipidaemic agents to
hypertension treatment regimens can be beneficial,
lessening target organ lesions and possibly reducing
the number of cardiovascular events.3 The 3-hydro-
xyl-3–methylglutaryl-coenzyme A (HMG-CoA) re-
ductase inhibitors, or statins, are the most effective
low-density lipoprotein cholesterol-lowering drugs,
with significant benefits in the prevention of
primary and secondary cardiovascular disease.4–9
Endothelial dysfunction is an event that occurs
early in atherosclerosis and in hypertension.10 It is
one of the potential mechanisms linking cholesterol
with cardiovascular disease. In that context, insulin
resistance and progressive endothelial dysfunction
have a role in the pathogenesis of hypertension and
atherosclerosis.11 Recent studies have demonstrated
that the so-called pleiotropic effects of statins can
prevent cardiovascular remodelling in experimental
models of human disease.12,13 Dechend et al.,14
studying transgenic rats, found that, in addition to
the known lipid-lowering effect, statin treatment
reduced hypertension, myocardial hypertrophy and
vascular fibrosis. Other experimental studies, of
rosuvastatin and pravastatin, have shown that
statins slow the development of cardiovascular
hypertrophy, inflammation and glucose intoler-
ance.13,15,16 Although these experimental results
suggest that statins act simultaneously on endothe-
lial function, insulin resistance and myocardial
structure, efforts to translate such findings to the
clinical setting have been unsuccessful.
This study investigated the effect of fluvastatin
treatment on ambulatory blood pressure (ABP),
exercise blood pressure (EBP), myocardial structure,
endothelial function and insulin resistance in a
group of patients under treatment for hypertension.
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Materials and methods
We conducted a randomized, double-blind study
comparing fluvastatin (20mg) with placebo in
patients with primary hypertension that was classi-
fied as stage 1 hypertension, as defined in The
Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (JNC 7).17 A total of 50 patients
were enrolled in the study. The study was divided
into two phases, the selection/washout phase
(3 weeks) and the randomized treatment phase (12
months). During the selection/washout phase (visits
1 and 2, V1 and V2), patients received only placebo
and were taken off any antihypertensive or hypo-
lipidaemic agents. Patients entering the randomized
treatment phase then received either placebo or
fluvastatin throughout the 12-month study period,
with evaluations every 2 months (visits V3–V8).
All patients, regardless of group assignment, were
treated for hypertension with enalapril. If necessary,
the dose was increased or hydrochlorothiazide was
added as follows: step 1—enalapril, 10mg b.i.d.;
step 2—enalapril, 20mg b.i.d.; step 3—enalapril
(20mg b.i.d.)þhydrochlorothiazide (12.5mg per
day). With regard to previous therapies, both groups
were comparable in terms of exposition to anti-
hypertensive agents, before the wash-out period,
with a median 62% use of thiazide diuretics and
54% use of renin–angiotensin system blockers in
both groups, in comparable proportions.
The inclusion criteria were being between 18 and
65 years of age and having primary hypertension
that was classified as stage 1. Exclusion criteria were
as follows: stage 2 hypertension or any form of
secondary hypertension; secondary dyslipidaemia;
prior cardiovascular disease; endocrinopathy (in-
cluding diabetes mellitus); pneumopathy or nephro-
pathy of any origin; any pathology of the locomotor
system that could interfere with the treadmill test;
known hypersensitivity to fluvastatin; positive
pregnancy test and breastfeeding. Written informed
consent was obtained from all patients.
Clinical evaluation
The primary demographic and anthropometric data
collected were age (years), weight (kg), height (m)
and body mass index (kgm2). During all visits,
blood pressure was calculated as the mean of three
measurements taken while the patients were seated,
in accordance with JNC 7 recommendations.17
Clinical and biochemical parameters
At months 0, 2, 4, 8 and 12, the following
biochemical parameters were analysed: fasting glu-
cose, fasting insulinaemia, low-density lipoprotein
cholesterol, very low-density lipoprotein (VLDL)
cholesterol, high-density lipoprotein cholesterol
and triglycerides. Diabetes mellitus was diagnosed
according to the American Diabetes Association
criteria:18 Symptoms of diabetes plus casual plasma
glucose concentration X200mgdl1 without regard
to time since last meal or fasting plasma glucose
concentration X126mgdl1 (fasting defined as no
caloric intake for 8h) or 2-h post-load glucose
X200mgdl1 during oral glucose tolerance test. At
months 0 and 12, pregnancy tests were carried out.
At months 0, 6 and 12, albuminuria was measured
by 12-h nocturnal immunoturbidimetry, and ABP
was measured on the same day. At months 0 and 12,
insulin resistance was calculated by the homeostasis
model assessment of insulin resistance model
assessment of insulin resistance (HOMA-IR) index,19
calculated according to the following equation:
HOMA-IR¼ [fasting insulin (mUl1) fasting
glucose (mmol l1)]/22.5
The ABP was measured during a 24-h period at
months 0, 6 and 12 using an automatic monitor
(Model 90207; Spacelabs Healthcare, Issaquah, WA,
USA) fitted on the non-dominant arm. A percentage
of successful readings greater than 80% was con-
sidered adequate. At months 0, 6 and 12, treadmill
exercise stress tests were carried out using compu-
terized equipment (Challenger 5.0; Ecafix Indu´stria
e Come´rcio Ltda, Sa˜o Paulo, Brazil) including an
electrocardiograph and cardiac monitor for contin-
uous observation. To evaluate maximum systolic
blood pressure during exercise (ExSBPmax), we
measured blood pressure before the stress test and
once per minute thereafter, during treadmill activity,
using the Ellestad protocol.
At months 0, 6 and 12, patients underwent
echocardiography (Model SIM 5000; Escote Biome-
dica, Florence, Italy) in order to determine the left
ventricular mass index (LVMI), calculated in accor-
dance with the American Society of Echocardio-
graphy guidelines.
At months 0, 6 and 12, endothelial function was
evaluated by two independent, experienced radio-
logists. Measurements of the endothelium-depen-
dent and endothelium-independent vasodilator ca-
pacity of the brachial artery were made using
Doppler B-mode ultrasound.20 Evaluations were
made in separate tests:
Endothelium-dependent phase: Patients were put
at rest, in the horizontal decubitus position, for
10min. Intima–media thickness was measured in
the right brachial artery, at 2–15 cm above the crook
of the arm. Subsequently, a pneumatic cuff was
inflated to 290mmHg for 5min on the same arm,
resulting in total interruption of regional blood flow.
Fifteen seconds after deflating the cuff the max-
imum blood flow was measured during reactive
hyperaemia. After 90 s, three consecutive brachial
artery diameter measurements were taken during
diastole.
Endothelial-independent phase: Patients were put
at rest again for 10min, and brachial artery diameter
and regional blood flow were measured as above.
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Subsequently, 5mg of isosorbide mononitrate was
administered sublingually in pill form, followed by
an additional measurement of the arterial diameter
and regional blood flow.
Statistical analysis
For comparisons between the two groups, we used
the Student’s t-test for categorical variables and the
Wilcoxon test or Mann–Whitney test, as appropri-
ate, for continuous variables. To test for differences
over time, we used analysis of variance with
repeated measures. The chi-square test was used to
compare proportions between groups. Pearson’s
correlation test was used in order to identify
correlations between variables. For all tests, values
of Po0.05 were considered statistically significant.
Results
Baseline patient demographic data and test results
during the randomization period (visit V2) are
shown in Table 1. During the wash-out phase, six
patients were excluded: four due to stage 2 hyper-
tension and two due to a diagnosis of diabetes
mellitus. An additional four patients, three in the
fluvastatin arm and one in the placebo arm, dropped
out of the study. In the placebo group, one patient
was excluded because of the need for hypolipidae-
mic treatment. Therefore, 39 patients completed the
12-month treatment period. The mean age was 51
years. Males accounted for 10% of the placebo group
and 31.6% of the fluvastatin group. There was no
severity of hypertension imbalance before the wash-
out period. There were no statistically significant
differences between the groups in terms of body
mass index or lipid profile. Similarly, during
randomization no significant differences between
groups were observed in the values obtained for uric
acid, creatinine, microalbuminuria, HOMA-IR in-
dex, blood pressure (ABP or ExSBPmax) or LVMI.
During the study period, there were no differences
between the groups in terms of the type or number of
antihypertensive drugs taken (mean, 1.5 prescrip-
tions per patient).
At the end of the 12-month study period, no
statistically significant differences were found be-
tween the placebo and fluvastatin groups in terms of
high-density lipoprotein cholesterol or triglyceride
plasma levels (Table 2). In addition, there were no
differences in terms of serum creatinine or micro-
albuminuria values. Over the course of the study,
there was, as expected, a significant reduction in
low-density lipoprotein cholesterol in the fluvasta-
tin group but not in the placebo group.
Blood pressure measurements are shown in
Table 3. No significant differences in ABP or resting
blood pressure were observed. However, compared
with patients in the placebo group, those treated
with fluvastatin demonstrated a statistically signifi-
cant (Po0.05) reduction in ExSBPmax by the end of
treatment (Figure 1), with a concomitant reduction
in LVMI (Figure 2). No association between systolic
Table 1 Baseline characteristics
Placebo Fluvastatin P
N¼20 N¼ 19
Age, years 51±8 51±10 0.78
Male 10.00% 31.6%
Bmi V2 29±5 27±3 0.86
CHOL V2, mgdl1 252±3 239±4 0.26
HDL V2, mgdl1 51±12 44±13 0.12
LDL V2, mgdl1 161±38 165±32 0.76
TG V2, mgdl1 187±175 195±149 0.87
Uric acid V2, mgdl1 4.6±1 4.9±1.7 0.43
Creatinine V2, mgdl1 0.88±0.19 0.88±0.16 0.98
MICRO V2, mg per g cr 11.3±15.3 6.3±6.8 0.2
HOMA-IR V2 4.38±6.13 3.34±1.73 0.48
Pre SBP V2, mmHg 151±15 149±16 0.61
ExSBPmax V2, mmHg 187±20 190±20 0.66
ABP SBP V2, mmHg 138±12 139±14 0.78
ABP DBP V2, mmHg 86±9 87±11 0.77
ABP SL V2, % 57±31 54±28 0.76
ABP DL V2, % 46±28 43±30 0.76
LVMI V2 116±34 99±36 0.13
Abbreviations: ABP DBP, ambulatory blood pressure, diastolic blood
pressure; ABP DL, ambulatory blood pressure, diastolic load; ABP
SBP, ambulatory blood pressure, systolic blood pressure; ABP SL,
ambulatory blood pressure, systolic load; BMI, body mass index;
CHOL, cholesterol; ExSBPmax, maximum systolic blood pressure
during exercise; HOMA-IR, Homeostasis Model Assessment of Insulin
Resistance; HDL, high-density lipoprotein cholesterol; LDL, low-
density lipoprotein cholesterol; LVMI, left ventricular mass index;
MICRO, microalbuminuria; Pre SBP, pre-exercise systolic blood
pressure; TG, triglycerides; V2, visit 2 (washout phase).
Data are means±s.d.
Table 2 Lipid profile and renal function
Placebo Fluvastatin P
N¼ 20 N¼19
CHOL V2, mgdl1 252±32 239±40 0.26
CHOL V5, mgdl1 236±32 208±31 0.008*
CHOL V8, mgdl1 240±35 207±36 0.008*
HDL V2, mgdl1 51±12 44±13 0.12
HDL V5, mgdl1 53±12 47±15 0.15
HDL V8, mgdl1 53±14 48±15 0.27
LDL V2, mgdl1 161±38 165±32w 0.76
LDL V5, mgdl1 151±37 129±22 0.04*
LDL V8, mgdl1 155±27 127±30w 0.008*
TG V2, mgdl1 187±175 195±149 0.78
TG V5, mgdl1 167±101 185±172 0.76
TG V8, mgdl1 177±106 185±143 0.84
Cr V2, mgdl1 0.88±0.19 0.88±0.16 0.98
Cr V5, mgdl1 0.91±0.11 0.92±0.16 0.71
Cr V8, mgdl1 0.94±0.13 0.91±0.15 0.54
MICRO V2, mg per g Cr 11±15 6±7 0.2
MICRO V5, mg per g Cr 14±19 6±6 0.1
MICRO V8, mg per g Cr 10±15 4±3 0.13
Abbreviations: CHOL, cholesterol; Cr, creatinine; HDL, high-density
lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol;
Micro, microalbuminuria; TG, triglycerides; V2, visit 2 (washout
phase); V5, visit 5 (month 6); V8, visit 8 (month 12).
Data are means±s.d.
*Po0.05 fluvastatin vs placebo; wPo0.05 fluvastatin V2 vs fluvastatin V8.
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exercise blood pressure and/or changes in left
ventricular mass index was observed. These results
remained consistent when the proportion of hyper-
trophic patients between groups was considered
(64.1% hypertrophic and 35.9% non-hypertrophic).
No significant differences between the placebo
and fluvastatin groups were found for artery
diameter or blood flow (endothelium-dependent or
endothelium-independent), either during randomi-
zation or at the end of the 12-month study period
(Table 4). Endothelial function was not found to
correlate with ExSBPmax or LVMI, at any time
during the study. In addition, at the study endpoint,
lipid profile was not correlated with endothelial
function, LVMI, ExSBPmax or HOMA-IR index.
The HOMA-IR index values for the placebo and
fluvastatin groups are shown in Figure 3. There was
no difference in anti-hypertensive drugs therapy
before the wash-out period and between the wash-
out phase and the end of the study, but there was a
significant reduction in the HOMA-IR index in the
fluvastatin group.
Discussion
In the population studied (patients with stage 1
hypertension and without cardiovascular disease),
ExSBPMax V2 ExSBPMax V5 ExSBPMax V8
0
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FLUVASTATIN
*
187 ± 20 190 ± 20
196 ± 19
189 ± 18 192 ± 23
175 ± 18
Figure 1 Maximum systolic blood pressure during exercise
(ExSBPmax), in mmHg, at visits V2 (washout), V5 (month 6)
and V8 (month 12). *Po0.05 for fluvastatin vs placebo.
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Figure 2 Left ventricular mass index (LVMI) at visits V2
(washout), V5 (month 6) and V8 (month 12). *Po0.05 for
fluvastatin vs placebo.
Table 4 Endothelium results
Placebo Fluvastatin P
N¼20 N¼ 19
FEDF % V2 701±330 762±613 0.71
FEDd % V2 10±9 9±11 0.74
FEIF % V2 7±52 10±42 0.29
FEId % V2 8±10 10±13 0.58
FEDF % V8 598±392 763±451 0.26
FEDd % V8 10±9 14±13 0.27
FEIF % V8 30±70 4±29 0.08
FEId % V8 23±32 10±9 0.13
Abbreviations: FEDd, final endothelium dependent diameter; FEDF,
final endothelium dependent flux; FEId, final endothelium indepen-
dent diameter; FEIF, final endothelium independent flux; V2, visit 2
(washout phase); V8, visit 8 (month 12).
Data are means±s.d.
Table 3 Blood pressure results
Placebo Fluvastatin P
N¼ 20 N¼19
ABP SBP V2, mmHg 138±12 139±14 0.78
ABP SBPV5, mmHg 132±12 126±13 0.13
ABP SBPV8, mmHg 131±11 126±12 0.2
ABP DBP V2, mmHg 86±9 87±11 0.77
ABP DBP V5, mmHg 82±10 80±10 0.44
ABP DBP V8, mmHg 82±8 80±7 0.43
ABP SLV2, % 57±31 54±28 0.76
ABP SLV5, % 41±31 28±29 0.18
ABP SLV8, % 40±29 27±26 0.17
ABP DLV2, % 46±28 43±29 0.76
ABP DLV5, % 34±26 27±28 0.4
ABP DLV8, % 32±23 22±21 0.16
ExSBPmax V2, mmHg 187±20 190±20 0.66
ExSBPmax V5, mmHg 196±19 189±18 0.27
ExSBPmax V8, mmHg 192±23 175±18 0.032*
Pre SBP V2, mmHg 151±15 149±16 0.61
Pre SBP V5, mmHg 140±16 136±13 0.4
Pre SBP V8, mmHg 136±11 131±12 0.31
Abbreviations: ABP DBP, ambulatory diastolic blood pressure; ABP
DL, ambulatory blood pressure, diastolic load; ABP SBP, ambulatory
systolic blood pressure; ABP SL, ambulatory blood pressure, systolic
load; ExSBPmax, maximum systolic blood pressure during exercise;
Pre SBP, pre-exercise systolic blood pressure; V2, visit 2 (washout
phase); V5, visit 5 (month 6); V8, visit 8 (month 12).
Data are means±s.d.
*Po0.05 for fluvastatin vs placebo.
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adding fluvastatin to the hypertension treatment
regimen resulted in consistent reductions in LVMI
and HOMA-IR index by the end of treatment.
Similarly, ExSBPmax was reduced in the fluvastatin
group, despite similar office blood pressure and
ABP. We found that neither the lipid profile nor its
variations (data not shown) correlated with LVMI,
insulin resistance parameters or ExSBPmax.
Several studies have analysed the impact of HMG-
CoA reductase inhibitors on blood pressure in
different patient populations, with inconsistent
results. Although some studies have found that
statin therapy reduces blood pressure,21–26 there is
no consensus yet on this observation.24 In 1999,
Glorioso et al.26 demonstrated an attenuation of
blood pressure in hypercholesterolaemic, hyperten-
sive patients after a four-month course of pravasta-
tin. In a subsequent study, Terzoli et al.27 detected a
reduction in ABP, but not in resting blood pressure,
in a cohort treated with statins and anti-hyperten-
sive drugs. Recently, in a discerning meta-analysis
of 20 randomized, controlled studies, Strazzullo
et al.28 demonstrated a slight but significant reduc-
tion in blood pressure following HMG-CoA reduc-
tase inhibitor treatment. In our study, we found that
blood pressure reduction occurred independently of
changes in cholesterol levels. In agreement with
Terzoli et al.,27 we found that statin treatment
affected ExSBPmax but detected no effect on resting
blood pressure. It is of note that patients in our
study population were not selected based on their
lipid profiles and did not have any cardiovascular
disease that might influence blood pressure. In
addition, unlike the studies cited here, our study
included standardized treatment of hypertension for
all study subjects, such that any difference in blood
pressure in the treatment group would be primarily
attributable to statin therapy.
Wassmann et al.29 reported a reduction in blood
pressure among spontaneously hypertensive rats
treated with atorvastatin and found the reduction
to be associated with changes in the vasodilation
of aortic segments. The authors hypothesized that
the improvement in endothelial function was due
to downregulated expression of the angiotensin II
receptor AT1. The clinical relevance of these
observations was recently demonstrated by Ott
et al.30 in a study of 22 hypercholesterolaemic
patients treated with rosuvastatin for 6 weeks. That
study found an increase in basal nitric oxide
synthase activity in patients treated with statins as
compared with patients in the placebo group. Our
study of endothelial function did not reveal varia-
tions in artery diameter or blood flow between
groups, and, in accordance with Ott et al.,30 did not
demonstrate any correlation between endothelial
function and treatment-related changes in lipid
profile, or between endothelial function and blood
pressure. The absence of an association with
endothelial function was consistent, regardless of
the type of blood pressure measurement (office
blood pressure, ABP or ExSBPmax). Different meth-
ods for measuring endothelial function might
explain why our results differed from those of Ott
et al. In addition, hypercholesterolaemia was not
considered during the selection of our patient
population, which might have resulted in a lesser
degree of endothelial dysfunction and subsequently
less change during treatment. Finally, patients in
our study already showed some degree of insulin
resistance at randomization, an effect that might
have influenced our endothelial function results,
despite the improved HOMA-IR index seen in the
fluvastatin group. In fact, although the numbers in
the diabetes group might be too small for clear
interpretation, findings from the ARBITER 2 trial
showed that abnormal glucose metabolism could
affect the analysis of vascular structure.11 Despite a
decrease in the carotid artery intima–media thick-
ness in patients treated with the combination of
statin and niacin, a similar improvement was not
observed in patients who had abnormal glycaemic
status at the beginning of treatment.11
Our study demonstrated that fluvastatin treatment
improves insulin resistance (HOMA-IR index). The
effect of statin treatment on insulin sensitivity is
controversial. The validity of HOMA-IR has been
evaluated by comparison with some gold standard
methods. HOMA-IR has been shown to correlate
well with insulin resistance index derived from the
euglycaemic clamp and from directly measured
insulin sensitivity.31 Sari et al.32 found no improve-
ment in HOMA-IR in 42 hypercholesterolaemic
patients treated with atorvastatin in a non-rando-
mized, open-label study. In contrast with our cohort,
the patients studied by Sari et al. had insulin
resistance indices within the normal range (mean,
Placebo Fluvastatin
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Figure 3 Insulin sensitivity. Homeostasis model assessment of
insulin resistance (HOMA-IR) index at visits V2 (washout) and V8
(month 12). *Po0.05 for V2 vs V8.
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1.8±0.6 for the HOMA-IR index). That factor,
together with the short 3-month study period of
Sari et al., might explain why that study detected no
improvement in HOMA-IR. As in our study, Sonmez
et al.33 reported an improvement in insulin resis-
tance in 35 hypercholesterolaemic patients treated
with fluvastatin. We also found that there was no
correlation between changes in patient lipid profile
and the observed improvement in insulin resistance,
suggesting potential fluvastatin pleiotropism. It also
appears that this benefit increases in direct propor-
tion to the magnitude of the change in insulin
resistance. In fact, in 25 female patients with
metabolic syndrome, the administration of pravas-
tatin resulted in pronounced improvements in
insulin resistance.34
A post hoc analysis of the West of Scotland
Coronary Prevention Study demonstrated pravasta-
tin’s benefits in a large population sample, showing
a 30% reduction in the incidence of diabetes
mellitus,35 although that finding was not confirmed
in another major study.36 On the other hand, the
study of Koh et al.37 addressed whether atorvastatin
might decrease insulin sensitivity and increase
ambient glycaemia in hypercholesterolaemic pa-
tients. It is not clear why atorvastatin has beneficial
metabolic actions in some studies but not in others.
The mechanisms by which statins might act to
improve insulin resistance remain unclear. An
improvement in endothelial function would be one
reasonable hypothesis. However, data collected in
our study do not support that theory.
The effect of statins on ventricular remodelling
has recently been considered more thoroughly.
Using an murine model of angiotensin II-induced
hypertension, Xu et al.15 showed improvement in
diastolic left ventricular dysfunction with pravasta-
tin, as well as improvements in hypertrophy and left
ventricular remodelling. In agreement with our
findings, the attenuation of ventricular hypertrophy
observed by Xu et al. was not associated with
changes in blood pressure or lipid profile. The
authors found that the improvement in myocardial
remodelling was associated with a downregulation
of local mitogens (transforming growth factor-b and
metalloproteinases) and of cytokines (interleukin-6
and transforming growth factor-a). These results
confirm the findings of a previous study by
Cirricone et al.,38 in which the impact of ventricular
volume overload was attenuated by rosuvastatin
treatment in Sprague–Dawley rats. Statin use re-
sulted in lower transforming growth factor-b, fibro-
nectin and procollagen expression in ventricular
tissue. In human subjects, few studies have inves-
tigated the possible benefits of statins on ventricular
morphology and function. De Lorgeril et al.39
showed an improvement in cardiac performance,
as measured by cardiac stress scintigraphy, in 32
patients treated with simvastatin for 12 weeks.
In another study, the impact of simvastatin on ventri-
cular function was studied in hypercholesterolaemic
patients during 6 months of treatment.40 In contrast
to the benefits seen in our study, statin treatment
did not result in significant alteration of left
ventricular function, as evaluated by echocardiogra-
phy. As with conflicting data on the impact of
statins on insulin resistance, it is possible in this
case that the amount of time needed to show a
benefit from HMG-CoA reductase inhibitors on
ventricular remodelling was greater than that en-
compassed by the study period.
In summary, our study demonstrates simulta-
neous benefits of treatment with a HMG-CoA
reductase inhibitor (fluvastatin) on blood pressure
during exercise, insulin resistance and ventricular
remodelling in patients under treatment for hyper-
tension. The observed benefits were not associated
with other effects of statin treatment, including the
reduction in low-density lipoprotein cholesterol
levels and changes in endothelial function. It is
likely that the results are explained by statin
pleiotropism.
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